Single common courses of remission induction multi-agent combination chemotherapy for all the eligible patients For Standard Risk group(SR), 4 courses of intensification multi-agent combination chemo

2 trials

Sponsors

Japanese Pediatric Leukemia/Lymphoma Study Group(JPLSG)

Conditions

Acute myeloid Leukemia Myelodysplastic syndrome

Phase 2

Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-D05: Phase II Study of Risk Stratified Multi-drug Chemotherapy on Down Syndrome with Newly diagnosed Childhood Acute Myeloid Leukemia

Active, not recruitingJPRN-UMIN000000989

Japanese Pediatric Leukemia/Lymphoma Study Group(JPLSG)Acute myeloid Leukemia Myelodysplastic syndrome

Start: 2008-01-01Target: 73Updated: 2026-06-29

Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-D11:A Phase II Study to evaluate the feasibility and utility of minimal residual disease (MRD) for childhood acute myeloid leukemia with Down syndrome

Active, not recruitingJPRN-UMIN000007237

Japanese Pediatric Leukemia/Lymphoma Study Group(JPLSG)Acute myeloid Leukemia Myelodysplastic syndrome

Start: 2012-03-01Target: 50Updated: 2026-06-29

Related Papers

Risk-Oriented Therapy for Myeloid Leukemia of Down Syndrome: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG)

Blood2014-12-061 citations